Cerecor Inc. Common Stock
Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis; CERC-006, an oral mTORC1/2 inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody that is in phase 2 clinical trial for the treatment of COVID-19 acute respiratory distress syndrome, as well as for the treatment of pediatric-onset Crohn's diseases. In addition, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. Cerecor Inc. has a collaboration agreement with The Frontiers in Congenital Disorders of Glycosylation Consortium on pivotal trial of CERC-801 for the treatment of Phosphoglucomutase-1 deficiency related congenital disorders of glycosylation. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
CERC Overview
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$0.0000 |
Previous Close Volume |
0 |
Latest News
- Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants 12 Nov 2024 07:05:04
-
Avalo Therapeutics to Present at Upcoming Investor Conferences
11 Nov 2024 07:05:17
https://ir.avalotx.com/press-releases/detail/195/avalo-therapeutics-to-present-at-upcoming-investor
- Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates 07 Nov 2024 07:01:37
- Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa 08 Oct 2024 07:05:34
-
Avalo Announces Participation in September Investor Conferences
04 Sep 2024 07:01:35
https://ir.avalotx.com/press-releases/detail/192/avalo-announces-participation-in-september-investor
- Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates 12 Aug 2024 07:05:46
- Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer 16 Jul 2024 07:05:35
- Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa 09 Jul 2024 07:05:40
- Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer 24 Jun 2024 16:05:59
- Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit 17 Jun 2024 07:35:46
- Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates 13 May 2024 07:35:52
- Avalo Therapeutics Appoints Biotech Leaders to Board of Directors 02 Apr 2024 07:06:04
- Avalo Reports 2023 Financial Results and Provides Business Updates 29 Mar 2024 16:06:04
-
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
27 Mar 2024 16:06:05
https://ir.avalotx.com/press-releases/detail/183/avalo-acquires-anti-il-1-mab-and-announces-private